Mount Vernon Cancer Centre Review, Harrow interested

MVCCIn a forthcoming presentation to the Harrow Health and Social Care Scrutiny, the NHS England and NHS Improvement update on the review of all of the cancer services provided by Mount Vernon Cancer Centre (MVCC).
The Centre is run by East and North Hertfordshire NHS Trust and the services delivered from a site in North Middlesex managed by the Hillingdon Hospitals NHS Foundation Trust. It is a stand alone cancer centre.
The services include outpatient chemotherapy, nuclear medicine, brachytherapy and haematology, provided by the Mount Vernon team, as well as radiotherapy and inpatient services.
Geographical Distribution of Patients shows that Harrow CCG (Clinical Commissioning Group) has referred 3,254 patients to Mount Vernon Cancer Centre in the last three years.
As people live longer, more people with cancer are also living with other illnesses or conditions which require treatment alongside their cancer treatment. This cannot be done at MVCC and therefore they have arrangements with 16 other hospitals to provide the support that is not available at MVCC – this can cause problems when those other hospitals have their own priorities, such as anaesthetics support during the first covid peak. This also means patients have to travel much further for some treatment, for example patients requiring treatment for haematological malignancy travel to UCLH (University College London Hospitals).
The review is run by a Programme Board which is led by the Regional Director of Specialised Commissioning for NHS England in the East of England who are looking at the future clinical model of the services, including whether there is a single new cancer centre, or whether there is also a day hospital (ambulatory centre) on a second site, or even if there is a variation of one of those.
The clinical team is going to make a recommendation in December. They are not looking at the location of the services.
Click here to find out more about the review or how to let know your views.